이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF (RELAX-AHF-ASIA)

2019년 6월 12일 업데이트: Novartis Pharmaceuticals

A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.

연구 개요

상태

종료됨

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

876

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 대만
      • Changhua, 대만, 50006
        • Novartis Investigative Site
      • Kaohsiung, 대만, 80756
        • Novartis Investigative Site
      • Kaohsiung City, 대만, 83301
        • Novartis Investigative Site
      • New Taipei, 대만, 22060
        • Novartis Investigative Site
      • Taichung, 대만, 40447
        • Novartis Investigative Site
      • Taipei, 대만, 10002
        • Novartis Investigative Site
      • Taipei, 대만, 11217
        • Novartis Investigative Site
      • Taipei, 대만, 10449
        • Novartis Investigative Site
      • Taoyuan, 대만, 33305
        • Novartis Investigative Site
      • Yilan, 대만, 26058
        • Novartis Investigative Site
  • 대한민국
      • Busan, 대한민국, 602739
        • Novartis Investigative Site
      • Gwangju, 대한민국, 61469
        • Novartis Investigative Site
      • Incheon, 대한민국, 405 760
        • Novartis Investigative Site
      • Seoul, 대한민국, 03080
        • Novartis Investigative Site
      • Seoul, 대한민국, 03722
        • Novartis Investigative Site
      • Seoul, 대한민국, 02841
        • Novartis Investigative Site
    • Bucheon Si
      • Gyeonggi do, Bucheon Si, 대한민국, 422-711
        • Novartis Investigative Site
    • Chungcheongbuk Do
      • Cheongju si, Chungcheongbuk Do, 대한민국, 28644
        • Novartis Investigative Site
    • Gangwon-do
      • Wonju, Gangwon-do, 대한민국, 26427
        • Novartis Investigative Site
    • Gyeonggi Do
      • Bundang Gu, Gyeonggi Do, 대한민국, 13620
        • Novartis Investigative Site
    • Korea
      • Seoul, Korea, 대한민국, 05505
        • Novartis Investigative Site
      • Seoul, Korea, 대한민국, 06351
        • Novartis Investigative Site
      • Seoul, Korea, 대한민국, 08308
        • Novartis Investigative Site
    • Seocho Gu
      • Seoul, Seocho Gu, 대한민국, 06591
        • Novartis Investigative Site
  • 레바논
      • Ashrafieh, 레바논, 166830
        • Novartis Investigative Site
      • Beirut, 레바논, 1107 2020
        • Novartis Investigative Site
      • Beirut, 레바논
        • Novartis Investigative Site
      • Hazmieh, 레바논, 470
        • Novartis Investigative Site
  • 말레이시아
      • Kuala Lumpur, 말레이시아, 59100
        • Novartis Investigative Site
      • Kuala Lumpur, 말레이시아, 50400
        • Novartis Investigative Site
    • MYS
      • Kuala Lumpur, MYS, 말레이시아, 56000
        • Novartis Investigative Site
    • Sabah
      • Kota Kinabalu, Sabah, 말레이시아, 88300
        • Novartis Investigative Site
    • Sarawak
      • Kuching, Sarawak, 말레이시아, 94300
        • Novartis Investigative Site
    • Selangor Darul Ehsan
      • Kuala Lumpur, Selangor Darul Ehsan, 말레이시아, 43000
        • Novartis Investigative Site
      • Sungai Buloh, Selangor Darul Ehsan, 말레이시아, 47000
        • Novartis Investigative Site
  • 싱가포르
      • Singapore, 싱가포르, 169609
        • Novartis Investigative Site
      • Singapore, 싱가포르, 117549
        • Novartis Investigative Site
  • 요르단
      • Amman, 요르단, 11183
        • Novartis Investigative Site
      • Amman, 요르단, 11184
        • Novartis Investigative Site
    • JOR
      • Amman, JOR, 요르단, 11152
        • Novartis Investigative Site
  • 인도
      • Rajasthan, 인도, 334003
        • Novartis Investigative Site
    • Delhi
      • New Delhi, Delhi, 인도, 110029
        • Novartis Investigative Site
    • Gujarat
      • Ahmedabad, Gujarat, 인도, 380054
        • Novartis Investigative Site
      • Vadodara, Gujarat, 인도, 390022
        • Novartis Investigative Site
    • Maharashtra
      • Nagpur, Maharashtra, 인도, 440010
        • Novartis Investigative Site
      • Nagpur, Maharashtra, 인도, 440012
        • Novartis Investigative Site
    • Tamil Nadu
      • Chennai, Tamil Nadu, 인도, 600101
        • Novartis Investigative Site
    • Telangana
      • Hyderabad, Telangana, 인도, 500082
        • Novartis Investigative Site
  • 일본
      • Osaka, 일본, 534-0021
        • Novartis Investigative Site
      • Saitama, 일본, 330 8503
        • Novartis Investigative Site
    • Aichi
      • Nagakute-city, Aichi, 일본, 480-1195
        • Novartis Investigative Site
      • Seto-city, Aichi, 일본, 489-8642
        • Novartis Investigative Site
    • Chiba
      • Kamogawa-city, Chiba, 일본, 2968602
        • Novartis Investigative Site
    • Ehime
      • Saijo-city, Ehime, 일본, 793-0027
        • Novartis Investigative Site
    • Fukuka
      • Chikushino-city, Fukuka, 일본, 818-8516
        • Novartis Investigative Site
    • Fukuoka
      • Fukuoka-city, Fukuoka, 일본, 810-0001
        • Novartis Investigative Site
      • Fukuoka-city, Fukuoka, 일본, 811-0213
        • Novartis Investigative Site
      • Fukuoka-city, Fukuoka, 일본, 815-8588
        • Novartis Investigative Site
      • Iizuka-city, Fukuoka, 일본, 820-8505
        • Novartis Investigative Site
      • Kurume-city, Fukuoka, 일본, 830-8543
        • Novartis Investigative Site
      • Kurume-city, Fukuoka, 일본, 830-8577
        • Novartis Investigative Site
    • Gifu
      • Ogaki-city, Gifu, 일본, 503-8502
        • Novartis Investigative Site
    • Hokkaido
      • Kushiro-city, Hokkaido, 일본, 085-0062
        • Novartis Investigative Site
      • Sapporo-city, Hokkaido, 일본, 006-8555
        • Novartis Investigative Site
    • Hyogo
      • Amagasaki city, Hyogo, 일본, 660 8550
        • Novartis Investigative Site
      • Kobe-City, Hyogo, 일본, 654-0155
        • Novartis Investigative Site
    • Ibaraki
      • Mito-city, Ibaraki, 일본, 311-4198
        • Novartis Investigative Site
    • Ishikawa
      • Kanazawa, Ishikawa, 일본, 920 8650
        • Novartis Investigative Site
    • Kagawa
      • Kanonji-city, Kagawa, 일본, 769-1695
        • Novartis Investigative Site
      • Takamatsu city, Kagawa, 일본, 760 8557
        • Novartis Investigative Site
    • Kanagawa
      • Kawasaki-city, Kanagawa, 일본, 211-8533
        • Novartis Investigative Site
      • Yokohama city, Kanagawa, 일본, 232 0024
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, 일본, 236 0051
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, 일본, 227-8501
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, 일본, 231-8682
        • Novartis Investigative Site
    • Kochi
      • Kochi city, Kochi, 일본, 781 8555
        • Novartis Investigative Site
    • Kumamoto
      • Kumamoto-city, Kumamoto, 일본, 861-4193
        • Novartis Investigative Site
      • Yatsushiro-city, Kumamoto, 일본, 866-8660
        • Novartis Investigative Site
    • Kyoto
      • Kyoto-city, Kyoto, 일본, 607-8062
        • Novartis Investigative Site
      • Uji-city, Kyoto, 일본, 611-0042
        • Novartis Investigative Site
    • Miyagi
      • Sendai-city, Miyagi, 일본, 981-3133
        • Novartis Investigative Site
    • Nagano
      • Nakano-city, Nagano, 일본, 383-8505
        • Novartis Investigative Site
      • Saku-city, Nagano, 일본, 3850051
        • Novartis Investigative Site
      • Ueda-city, Nagano, 일본, 386-8610
        • Novartis Investigative Site
    • Niigata
      • Niigata-city, Niigata, 일본, 950-1197
        • Novartis Investigative Site
    • Osaka
      • Osaka-city, Osaka, 일본, 540-0006
        • Novartis Investigative Site
    • Saitama
      • Kawaguchi-city, Saitama, 일본, 333-0842
        • Novartis Investigative Site
      • Sayama-city, Saitama, 일본, 350-1323
        • Novartis Investigative Site
      • Wako-city, Saitama, 일본, 351-0102
        • Novartis Investigative Site
    • Shiga
      • Kusatsu city, Shiga, 일본, 525 8585
        • Novartis Investigative Site
    • Shizuoka
      • Hamamatsu-city, Shizuoka, 일본, 430-8558
        • Novartis Investigative Site
      • Kakegawa-city, Shizuoka, 일본, 436-8555
        • Novartis Investigative Site
    • Tokyo
      • Akishima-city, Tokyo, 일본, 196-0003
        • Novartis Investigative Site
      • Chuo ku, Tokyo, 일본, 104-8560
        • Novartis Investigative Site
      • Hachioji-city, Tokyo, 일본, 192-0918
        • Novartis Investigative Site
      • Itabashi-ku, Tokyo, 일본, 173-8610
        • Novartis Investigative Site
      • Musashino-city, Tokyo, 일본, 180-8610
        • Novartis Investigative Site
      • Shinagawa ku, Tokyo, 일본, 141 8625
        • Novartis Investigative Site
      • Shinagawa-ku, Tokyo, 일본, 142-8666
        • Novartis Investigative Site
    • Wakayama
      • Tanabe-city, Wakayama, 일본, 646-8558
        • Novartis Investigative Site
  • 중국
      • Beijing, 중국, 100050
        • Novartis Investigative Site
      • Chongqing, 중국, 400037
        • Novartis Investigative Site
      • Shanghai City, 중국
        • Novartis Investigative Site
    • Beijing
      • Beijing, Beijing, 중국, 100039
        • Novartis Investigative Site
      • Beijing, Beijing, 중국, 100037
        • Novartis Investigative Site
    • Gansu
      • Lanzhou, Gansu, 중국, 730030
        • Novartis Investigative Site
    • Guangdong
      • Guangzhou, Guangdong, 중국, 51000
        • Novartis Investigative Site
      • Guangzhou, Guangdong, 중국, 510515
        • Novartis Investigative Site
    • Jiangsu
      • Suzhou, Jiangsu, 중국, 215006
        • Novartis Investigative Site
      • Yangzhou, Jiangsu, 중국
        • Novartis Investigative Site
    • Liaoning
      • Shenyang, Liaoning, 중국, 110000
        • Novartis Investigative Site
      • Shenyang, Liaoning, 중국, 110003
        • Novartis Investigative Site
    • Shanghai
      • Jinshan, Shanghai, 중국, 201508
        • Novartis Investigative Site
      • Shanghai, Shanghai, 중국, 200032
        • Novartis Investigative Site
    • Shanxi
      • Xian, Shanxi, 중국, 710061
        • Novartis Investigative Site
    • Tianjin
      • Tianjin, Tianjin, 중국, 300121
        • Novartis Investigative Site
    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310013
        • Novartis Investigative Site
      • Wenzhou, Zhejiang, 중국, 325000
        • Novartis Investigative Site
  • 태국
      • Bangkok, 태국, 10330
        • Novartis Investigative Site
      • Bangkok, 태국, 10700
        • Novartis Investigative Site
      • Bangkok, 태국, 10400
        • Novartis Investigative Site
      • Chiang Mai, 태국, 50200
        • Novartis Investigative Site
      • Muang, 태국, 40002
        • Novartis Investigative Site
    • Hat Yai
      • Songkhla, Hat Yai, 태국, 90110
        • Novartis Investigative Site
  • 필리핀 제도
      • Makati City, 필리핀 제도, 1229
        • Novartis Investigative Site
      • Manila, 필리핀 제도, 1003
        • Novartis Investigative Site
      • Pasig City, 필리핀 제도, 1605
        • Novartis Investigative Site
      • Quezon City, 필리핀 제도, 1102
        • Novartis Investigative Site
      • Quezon City, 필리핀 제도, 1113
        • Novartis Investigative Site
      • San Juan City, 필리핀 제도, 1500
        • Novartis Investigative Site
    • Manila
      • Quezon City, Manila, 필리핀 제도, 1100
        • Novartis Investigative Site
    • Metro Manila
      • Manila, Metro Manila, 필리핀 제도, 1000
        • Novartis Investigative Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Male or female ≥ 18 years of age, with body weight ≤160 kg

  • Hospitalized for AHF; AHF is defined as including all of the following measured at any time between presentation (including the emergency department and outpatient clinic) and at the end of screening:

    • Persistent dyspnea at rest or with minimal exertion at screening and at the time of randomization
    • Pulmonary congestion on chest radiograph
    • Brain natriuretic peptide (BNP) ≥500 pg/mL or NT-proBNP ≥2,000 pg/mL
  • Systolic BP ≥125 mmHg at the start and at the end of screening
  • Able to be randomized within 16 hours from presentation to the hospital, including the emergency department and outpatient clinic
  • Received intravenous furosemide of at least 40 mg total (or equivalent) at any time between presentation (this includes outpatient clinic, ambulance, or hospital including emergency department) and the start of screening for the study for the treatment of the current acute HF episode
  • Renal impairment defined as an estimate glomerular filtration rate using the between presentation and randomization of ≥ 25 and ≤75mL/min/1.73m2, calculated using the Modification of Diet in Renal Disease formula (or modified sMDRD formula according to specific ethnic groups and local practice guidelines).

Exclusion Criteria:

  • Dyspnea primarily due to non-cardiac causes
  • Temperature >38.5°C (oral or equivalent), sepsis, active and clinically significant infection requiring IV anti-microbial treatment or known presence or evidence of Human Immunodeficiency Virus (HIV) infection (based on history and/or clinical findings, including laboratory results obtained during screening period).

  • Clinical evidence of acute coronary syndrome currently or within 30 days prior to enrollment

    *Patients with systolic blood pressure >180 mmHg at the end of screening

  • AHF due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate <45 beats per minute, or atrial fibrillation/flutter with sustained ventricular response of >130 beats per minute

  • Hepatic disease unrelated to Heart Failure etiology and as determined by any one of the following: AST and/or ALT values exceeding 3 X ULN and/or bilirubin > 1.5 X ULN at screening or history of hepatic encephalopathy, esophageal varices, or portacaval shunt, or a diagnosis of cirrhosis by any means, or evidence of chronic Hepatitis B (presence of hepatitis B surface antigen production: positive HBsAg), or chronic Hepatitis C infection (presence of Hepatitis C genetic replication: positive Hepatitis C viral RNA, based on history and/or clinical findings, including laboratory results obtained during screening period).

    *Significant uncorrected left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area <1.0 cm2 or mean gradient >50 mmHg on prior or current echocardiogram), and severe mitral stenosis

  • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past year with a life expectancy less than 1 year

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: Placebo
Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
의약품: 위약
정맥 주입
다른: Standard of CareTherapy
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
실험적: Serelaxin
Patients will receive continuous intravenous infusion of serelaxin(30 µg/kg/day) for 48 hours.
다른: Standard of CareTherapy
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
의약품: 세릴락신
정맥 주입

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percentage of Patients With a Clinical Composite Endpoint of Treatment Success, Treatment Failure, or no Change.
기간: through day 5
The trichotomous clinical composite endpoint of treatment success, treatment failure, or no change. Treatment success defined as improvement of dyspnea by Likert scale and at least 2 points improvement by at least 2 physician assessed signs and symptoms (orthopnea, rales edema, and jugular venous pulse) at Day 2; treatment failure defined as worsening heart failure, death, or re-hospitalization due to heart failure or renal failure through Day 5; no change defined as neither the criteria for treatment success nor the criteria for treatment failure was met through Day 5.
through day 5

2차 결과 측정

결과 측정
측정값 설명
기간
Time to WHF
기간: Through Day 5
Results are given in terms of number of participants with at least one worsening heart failure (WHF) event through day 5 (pre-defined timeframe).
Through Day 5
Time to CV Death
기간: Through Day 180
analysis of time to CEC CV death through day 180 : results are given in terms of number of participants with CV death event through day 180 (pre-defined timeframe).
Through Day 180
Time to All-cause Death
기간: Through Day 180
Results are given in terms of number of participants with all cause death event through day 180 (pre-defined timeframe).
Through Day 180
Time to Moderate or Marked Improvements in Dyspnea by Likert Scale, Expressed in Days
기간: Through Day 5
Time to event is computed as the number of days from randomization to moderate or marked improvements in dyspnea by Likert scale
Through Day 5
Dyspnea by VAS-AUC Changes
기간: Through Day 5
Change from baseline in Dyspena by VAS-AUC through Day 5, expressed in mm-hours
Through Day 5
Length of Intensive Care Unit (ICU) and/or Coronary Care Unit (CCU) Stay for the Index AHF Hospitalization
기간: Up to day 30
Length of stay will be defined as the hospitalization discharge date and the time minus the baseline date and time plus 1 day
Up to day 30
Renal Dysfunction and Prevention of Worsening of Renal Function
기간: Through Day 5
number of participants with renal dysfunction or in-hospital worsening of renal function through Day 5
Through Day 5
Time to Re-hospitalization Due to Heart Failure and Renal Impairment
기간: Through Day 180
Time to event is computed as the number of days from randomization to re-hospitalization due to Heart Failure and renal impairment
Through Day 180
Time to CV Death or Re-hospitalization Due to Heart Failure/ Renal Failure
기간: Through Day 180
Results are given in terms of number of participants with CV death or at least one re-hospitalization due to Heart Failure through day 180 (pre-defined timeframe).
Through Day 180
Time to In-hospital Worsening Heart Failure Through Day 5
기간: Through Day 5
Results are given in terms of number of participants with at least one in-hospital worsening heart failure through day 5 (pre-defined timeframe). In-hospital worsening heart failure is defined by symptoms only, signs only, and both symptoms and signs.
Through Day 5
Use of Loop Diuretic and Vasoactive Agents
기간: Through Day 5
Number of patients reported with use of loop diuretic and vasoactive agents from randomization through Day 5
Through Day 5
Change From Baseline in Cardio-renal Biomarkers
기간: Day 2 and Day 5
Day 2 and Day 5
Number of Patients Reported With Total Adverse Events, Serious Adverse Events and Death.
기간: For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.
To evaluate the safety and tolerability of intravenous serelaxin in AHF patients, number of patients with total adverse events, serious adverse events and death will be analyzed.
For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Novartis Pharmaceuticals

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2014년 3월 12일

기본 완료 (실제)

2017년 3월 27일

연구 완료 (실제)

2017년 6월 16일

연구 등록 날짜

최초 제출

2013년 11월 20일

QC 기준을 충족하는 최초 제출

2013년 12월 9일

처음 게시됨 (추정)

2013년 12월 11일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2019년 8월 2일

QC 기준을 충족하는 마지막 업데이트 제출

2019년 6월 12일

마지막으로 확인됨

2019년 6월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • CRLX030A2302

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

급성 심부전에 대한 임상 시험

위약에 대한 임상 시험

유사한 임상시험 검색

스폰서 및 공동 작업자

건강 상태

약물 개입

CROs by country

CROs in Jordan

정황

희귀 질병

약물 개입

식이 보충제

스폰서 / 협력자

위치

3
구독하다